Press Releases - 2026-09-21
Gallop Oncology – LYT-200
PureTech Announces Successful End-of-Phase 1 Meeting with U.S . Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Press Releases - 2026-09-09
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Press Releases - 2026-08-25
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Press Releases - 2026-07-13
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Press Releases - 2026-07-02
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Press Releases - 2026-07-02
Celea Therapeutics – Deupirfenidone (LYT-100)
Other
PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Press Releases - 2026-06-09
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
